RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia

Stock News

Mar 02

RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as "bad cholesterol" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1132294830"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132294830\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132294830?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 08:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132294830","market":"us","top_or_hot":-1,"title":"RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia","media":"Stock News","content":"<p>RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-02 08:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"","article_id":"1132294830","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132294830","pubTimestamp":1772410695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"III":"信息服务","06938":"瑞博生物-B","BK1161":"生物科技","BK4134":"信息科技咨询与其它服务"},"translate_title":"RIBOLIFE-B(06938)将于中国开始针对高脂血症的RBD7022注射液的III期试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1,"III":1},"content_text":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}